Targeting the Pedunculopontine Nucleus in Parkinson's Disease: Time to Go Back to the Drawing Board
Overview
Authors
Affiliations
Breit S, Milosevic L, Naros G, Cebi I, Weiss D, Gharabaghi A J Parkinsons Dis. 2023; 13(4):563-573.
PMID: 37092235 PMC: 10357146. DOI: 10.3233/JPD-225031.
Kroeger D, Thundercliffe J, Phung A, De Luca R, Geraci C, Bragg S Sleep. 2022; 45(12).
PMID: 36170177 PMC: 9742893. DOI: 10.1093/sleep/zsac242.
Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease.
Albin R, van der Zee S, van Laar T, Sarter M, Lustig C, Muller M Prog Brain Res. 2022; 269(1):345-371.
PMID: 35248201 PMC: 8957710. DOI: 10.1016/bs.pbr.2022.01.011.
Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson's disease.
Cury R, Pavese N, Aziz T, Krauss J, Moro E NPJ Parkinsons Dis. 2022; 8(1):8.
PMID: 35017551 PMC: 8752758. DOI: 10.1038/s41531-021-00276-6.
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Bohnen N, Costa R, Dauer W, Factor S, Giladi N, Hallett M Mov Disord. 2021; 37(2):253-263.
PMID: 34939221 PMC: 10122497. DOI: 10.1002/mds.28883.